PubMed · 12510447
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
Michael Kleerekoper. 2002. Routine bone densitometry in elderly men?. https://doi.org/10.3810/pgm.2002.12.1371
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
OBJECTIVES: The aim of this study was to observe hysterectomized postmenopausal women (without progestogen, which could interfere in the results), using oral-conjugated oestrogen 0.625 mg daily (n=13) or 17beta-estradiol transdermal patches delivering 50 microg daily (n=10) during 12 months, and to evaluate the treatment effects on body composition, visceral fat distribution, energy expenditure and substrate oxidation. METHODS: We studied 23 postmenopausal women using oral-conjugated oestrogen (Premarin) 0.625 mg daily (n=13) or transdermal oestrogen patches (Systen TTS) 50 microg daily (n=10). Body composition was measured by DEXA, visceral adipose tissue areas were measured by abdominal computed tomography, and energy expenditure, fat oxidation and carbohydrate oxidation were measured by indirect calorimetry (Deltatrac Metabolic Monitor). RESULTS: There were: (1) a decrease in IGF-I and an increase in GH levels in the oral group and no change in the transdermal group; (2) a increase in lean body mass in the transdermal group and a decrease in the oral group; (3) a increase in total body fat mass in the oral group and no change in the transdermal group; (4) an increases in total bone mass and in total bone mineral density in the transdermal group and no change in the oral group; (5) an increase in lipid oxidation in the transdermal group and a decrease in the oral group, and (6) no significantly change about weight, visceral adipose tissue areas and energy expenditure in both groups. CONCLUSIONS: The administration route of oestrogen replacement therapy in postmenopausal women confers distinct and divergent effects on body composition and substrate oxidation during 12-months treatment.
This study examined whether participation in high-impact sports during adolescence and adulthood contributes to bone health in males aged 40 years. Data were analyzed on 154 Belgian men aged 13 years at study onset in 1969 and aged 40 years at the end of the 27-year follow-up. In a second analysis, subjects were divided into three groups according to their sports participation history: participation during adolescence and adulthood in high-impact sports (HH; n=18), participation during adolescence in high-impact sports and during adulthood in nonimpact sports or no sports (HN; n=15), and participation during adolescence and adulthood in nonimpact sports or no sports (NN; n=14). Body mass and impact loading during adulthood were significant predictors of total body bone mineral density (BMD) and lumbar spine BMD. Analysis of variance revealed significant differences for lumbar spine BMD between the HH (1.12 g/cm2) group and the HN (1.01 g/cm2) and NN (0.99 g/cm2) groups (F=5.07, p=0.01). Total body BMD was also higher in the HH group at age 40 years, but not significantly (F=3.17, p=0.0515). Covariance analyses for total body BMD and lumbar spine BMD, with body mass and time spent participating in sports as covariates, confirmed these results. Continued participation in impact sports is beneficial for the skeletal health of males aged 40 years.
Risedronate reduces the risk of vertebral fractures by up to 70% within the first year of treatment. Increases in bone mineral density or decreases in bone turnover markers explain only a portion of the anti-fracture effect, suggesting that other factors, such as changes in trabecular bone architecture, also play a role. Our objective was to determine the effects of risedronate on bone architecture by analyzing iliac crest bone biopsy specimens using three-dimensional microcomputed tomography (3-D micro CT). Biopsy specimens were obtained at baseline and after 1 year of treatment from women enrolled in a double-blind, placebo-controlled study of risedronate 5 mg daily for the prevention of early postmenopausal bone loss. Trabecular architecture deteriorated in the placebo group (n = 12), as indicated by a 20.3% decrease in bone volume (25.1% vs. 20.0%, P = 0.034), a 13.5% decrease in trabecular number (1.649 vs. 1.426 mm(-1), P = 0.052), a 13.1% increase in trabecular separation (605 vs. 684 microm, P = 0.056), and an 86.2% increase in marrow star volume (3.251 vs. 6.053 mm(3), P = 0.040) compared with baseline values. These changes in architectural parameters occurred in the presence of a concomitant decrease from baseline in lumbar spine bone mineral density (-3.3%, P = 0.002), as measured by dual energy x-ray absorptiometry. There was no statistically significant ( P < 0.05) deterioration in the risedronate-treated group (n = 14) over the 1-year treatment period. Comparing the actual changes between the two groups, the placebo group experienced decreases in bone volume (placebo, -5.1%; risedronate, +3.5%; P = 0.011), trabecular thickness (placebo, -20 microm; risedronate, +23 microm; P = 0.032), and trabecular number (placebo, -0.223 mm(-1); risedronate, +0.099 mm(-1); P = 0.010), and increases in percent plate (placebo, +2.79%; risedronate, -3.23%; P = 0.018), trabecular separation (placebo, +79 microm; risedronate, -46 microm; P = 0.010) and marrow star volume (placebo, +2.80 mm(3); risedronate, -2.08mm(3); P = 0.036), compared with the risedronate group. These data demonstrate that trabecular architecture deteriorated significantly in this cohort of early postmenopausal women, and that this deterioration was prevented by risedronate. Although there is no direct link in this study between fracture and preservation of architecture, it is reasonable to infer that the preservation of bone architecture may play a role in risedronate's anti-fracture efficacy.